UTHR8:00 AMUnited Therapeutics Corporation to Present at the Jefferies Global Healthcare Conferenceunither.com
UTHR5:15 PMUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026Trial Results • Phase 3ATS Breaking News session Sun, May 17, 2026unither.com
UTHR3:15 PMUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026Trial Results • Phase 3ATS 2026 presentation Sun, May 17, 2026unither.com
UTHR7:00 PMUnited Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trialunither.com
UTHR8:00 AMUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conferenceunither.com
UTHR7:30 AMUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026Presentation / Abstract • Phase 3unither.com
UTHR8:00 AMUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directorsunither.com
UTHR8:00 AMUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026unither.com
UTHR7:30 AMUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026Presentation / Abstractunither.com
UTHR8:00 AMUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failureunither.com
UTHR8:00 AMUnited Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2Trial Results • Phase 3unither.com
UTHR5:14 PMUnited Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of MedicineTrial Results • Phase 3unither.com
UTHR6:00 AMUnited Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Programunither.com
UTHR6:00 AMUnited Therapeutics Corporation to Present at the Leerink Global Healthcare Conferenceunither.com
UTHR5:30 AMUnited Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant EfficacyTrial Results • Phase 3unither.com